Background：Balstilimab is a novel, fully human monoclonal immunoglobulin G4 IgG4 designed to block PD-1 programmed cell death protein 1 from interacting with its ligands PD-L1 and PD-L2. PD-1 is a negative regulator of immune activation that is considered a foundational target within the immuno-oncology market.
